G Widmann1, V A Nguyen2, J Plaickner3, W Jaschke3. 1. Universitätsklinik für Radiologie, Medizinische Universität Innsbruck, Anichstr. 35, 6020, Innsbruck, Österreich. gerlig.widmann@i-med.ac.at. 2. Universitätsklinik für Dermatologie, Venerologie und Allergologie, Medizinische Universität Innsbruck, Anichstr. 35, 6020, Innsbruck, Österreich. 3. Universitätsklinik für Radiologie, Medizinische Universität Innsbruck, Anichstr. 35, 6020, Innsbruck, Österreich.
Abstract
BACKGROUND: The increasing use of immunotherapy in oncology increases the need for radiologic evaluation of frequent and severe immune-related adverse events. OBJECTIVE: Determination of the incidence and manifestation of radiologic and nuclear medicine findings of immune-related adverse events. MATERIAL AND METHODS: Literature review of clinical and imaging findings of immune-related adverse events induced by the immune checkpoint inhibitors ipilimumab, nivolumab and pembrolizumab. Findings are illustrated with pictorial examples and contrasted to other relevant differential diagnoses. RESULTS: The most frequent imaging manifestations are colitis, hepatitis, pancreatitis, hypophysitis, pneumonitis, arthritis and sarcoid-like lymphadenopathy. Severe to life-threatening complications may result from colitis, pneumonitis and hypophysitis. A clear differentiation from other autoimmune diseases and discrimination of immune-related and infectious pulmonary findings can be very difficult and need close multidisciplinary collaboration. CONCLUSION: Knowledge of clinical and imaging findings of adverse events induced by immunotherapy is essential for timely and adequate therapeutic decisions. In addition to staging and follow-up imaging, identification and monitoring of immune-related adverse events adds to the radiologic responsibility in oncologic care.
BACKGROUND: The increasing use of immunotherapy in oncology increases the need for radiologic evaluation of frequent and severe immune-related adverse events. OBJECTIVE: Determination of the incidence and manifestation of radiologic and nuclear medicine findings of immune-related adverse events. MATERIAL AND METHODS: Literature review of clinical and imaging findings of immune-related adverse events induced by the immune checkpoint inhibitors ipilimumab, nivolumab and pembrolizumab. Findings are illustrated with pictorial examples and contrasted to other relevant differential diagnoses. RESULTS: The most frequent imaging manifestations are colitis, hepatitis, pancreatitis, hypophysitis, pneumonitis, arthritis and sarcoid-like lymphadenopathy. Severe to life-threatening complications may result from colitis, pneumonitis and hypophysitis. A clear differentiation from other autoimmune diseases and discrimination of immune-related and infectious pulmonary findings can be very difficult and need close multidisciplinary collaboration. CONCLUSION: Knowledge of clinical and imaging findings of adverse events induced by immunotherapy is essential for timely and adequate therapeutic decisions. In addition to staging and follow-up imaging, identification and monitoring of immune-related adverse events adds to the radiologic responsibility in oncologic care.
Authors: Mizuki Nishino; Nikhil H Ramaiya; Mark M Awad; Lynette M Sholl; Jennifer A Maattala; Myriam Taibi; Hiroto Hatabu; Patrick A Ott; Philippe F Armand; F Stephen Hodi Journal: Clin Cancer Res Date: 2016-08-17 Impact factor: 12.531
Authors: Sree Harsha Tirumani; Nikhil H Ramaiya; Abhishek Keraliya; Nancy D Bailey; Patrick A Ott; F Stephen Hodi; Mizuki Nishino Journal: Cancer Immunol Res Date: 2015-06-22 Impact factor: 11.151
Authors: Matthew M K Chan; Richard F Kefford; Matteo Carlino; Arthur Clements; Nicholas Manolios Journal: J Immunother Date: 2015-01 Impact factor: 4.456
Authors: Kyung Won Kim; Nikhil H Ramaiya; Katherine M Krajewski; Jyothi P Jagannathan; Sree Harsha Tirumani; Amitabh Srivastava; Nageatte Ibrahim Journal: Invest New Drugs Date: 2013-02-14 Impact factor: 3.850
Authors: Alexander T Faje; Ryan Sullivan; Donald Lawrence; Nicholas A Tritos; Riley Fadden; Anne Klibanski; Lisa Nachtigall Journal: J Clin Endocrinol Metab Date: 2014-07-31 Impact factor: 5.958
Authors: Olga Venditti; Delia De Lisi; Marco Caricato; Damiano Caputo; Gabriella Teresa Capolupo; Chiara Taffon; Elisa Pagliara; Sofia Battisi; Anna Maria Frezza; Andrea Onetti Muda; Giuseppe Tonini; Daniele Santini Journal: BMC Cancer Date: 2015-03-01 Impact factor: 4.430